Assessing Bone Disorders in Kidney Transplant Recipients
Studies bone measurements to better assess mineral and bone disease in adults after kidney transplant.
Plain-language title generated from the registry record
Registry title: Assessment of Mineral and Bone Disorders in Kidney Transplant Recipients
Key facts
- Where
- Iași, RomaniaSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 20 and 70 years old?
Source: NCT07141043, who can take part
Where in Romania
- University of Medicine and Pharmacy "Grigore T. Popa"Iași, RomaniaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Grigore T. Popa University of Medicine and Pharmacy
- Trial code
- NCT07141043
- Record updated
- 26 August 2025
- Original description
This study aims to integrate bone measurements (including bone turnover markers (BTM), bone mineral density (BMD) measurement, vertebral fracture assessment (VFA), trabecular bone score (TBS) ) commonly used in the general population for primary osteoporosis evaluation to enhance the assessment of CKD-MBD.Read full original descriptionShow less
New Directions and Perspectives in the Assessment of Mineral and Bone Disorders in Kidney Transplant Recipients
This study aims to integrate bone measurements (including bone turnover markers (BTM), bone mineral density (BMD) measurement, vertebral fracture assessment (VFA), trabecular bone score (TBS) ) commonly used in the general population for primary osteoporosis evaluation to enhance the assessment of CKD-MBD.
Inclusion: HD group: Patients undergoing HD for at least 12 months, aged 20-70 years, after signing an informed consent; KTR group: Patients with successful KTx performed at least 12 months prior to their enrollment, aged 20-70 years old, after signing an informed consent. Subjects will be eligible for inclusion regardless of KTx immunosuppression regimen, pre-transplantation history, history of pre-transplant dialysis, or whether the kidney donation was from a living or deceased donor; GPO group: men and postmenopausal women diagnosed with primary osteopenia or osteoporosis, aged 50-70 years old, after signing an informed consent.
Exclusion: GPO group: The same as for HD + diabetes mellitus + prolonged glucocorticoid therapy (>7.5 mg Prednisone or equivalent for at least 3 months); HD group: Treatment with active bone therapies (excluding calcium and vitamin D); ongoing cancer treatment or recent history of malignancy, cirrhosis, recent major fractures, patients who have received transplants other than kidney, secondary causes of osteoporosis (other than CKD or transplant-related: primary hyperparathyroidism, hyperthyroidism, congenital bone disorders, sarcoidosis, severe bone trauma, malignant tumors, inflammatory bowel disease, endogenous Cushing syndrome, anti-estrogen/anti-androgen therapy, and anorexia nervosa), pregnancy and breast-feeding; KTR group: The same as for HD + return to dialysis + acute graft rejection.